It is possible that higher sensitivity in early-stage disease could be achieved with a broader assessment of tumor molecular profiles, including early mutational events (e.g., APC and TP53 which may be shared across all subclones) as well as copy-number variations and patterns of hyper- and hypomethylation [3, 18, 44, 45]. The gene discussed is TP53; the disease is neoplasm.